Filing Flows › Verrica Pharmaceuticals (VRCA) › Q2 2026 › vs Q1 2026
Verrica Pharmaceuticals (VRCA) Q2 2026 vs Q1 2026 (quarter over quarter)
Verrica Pharmaceuticals's revenue rose $839K (+17%) from $5.0M in Q1 2026 to $5.9M in Q2 2026.
Verrica Pharmaceuticals, Q2 2026: revenue $5.9M (-54% year over year), operating margin -223.4%, net loss $13.2M, operating cash flow −$9.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $5.9M | $5.0M | $839K | +17% |
| Net loss | $13.2M | $9.7M | $3.5M | +36% |
| Costs & expenses | $19.0M | $14.7M | $4.3M | +29% |
| Operating costs | $19.0M | $14.7M | $4.2M | +29% |
| Interest & other, net | $56K | −$33K | $89K | — |
| Research & development | $6.0M | $3.9M | $2.2M | +56% |
| SG&A | $10.3M | $10.0M | $360K | +4% |
| Other operating costs | $2.6M | $889K | $1.7M | +190% |
| Operating cash sources | $13.2M | $9.7M | $3.5M | +36% |
| Depreciation | $15K | $17K | −$2K | -12% |
| Share-based compensation | $1.2M | $897K | $316K | +35% |
| Working capital & other | $2.6M | −$395K | $3.0M | — |
| Cash used in operations | $9.3M | $9.2M | $115K | +1% |
| Net loss absorbed | $13.2M | $9.7M | $3.5M | +36% |
Questions
How much did Verrica Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Verrica Pharmaceuticals's revenue rose $839K (+17%) from $5.0M in Q1 2026 to $5.9M in Q2 2026.